DataMeds AI Says Helomics' ChemoFx Test Receives Humana Medicaid Coverage Policy; Shares Rise Pre-Bell

06:26 AM EDT, 10/12/2026 (MT Newswires) -- DataMeds AI (MEDS) said Monday its Helomics subsidiary received a Medicaid coverage determination from Humana (HUM) for its ChemoFx test in gynecologic cancers. The company said the test measures how a patient's live tumor cells respond to chemotherapy drugs. Under Humana's policy, eligible members with gynecologic cancers may qualify for coverage in cases including rare cancers without established treatment guidelines, initial biopsy or surgery, recurrent disease, treatment-resistant cancer or inability to tolerate recommended treatment, the company said. The policy took effect July 22, 2026, and does not apply to all Humana plans, it added. Shares of the company were up more than 38% in Monday's premarket activity. Price: 4.09, Change: +1.13, Percent Change: +38.08